Lead Product(s) : Penpulimab,Anlotinib Hydrochloride
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Akeso’s Penpulimab Combo for Hepatocellular Cancer Accepted by NMPA in China
Details : AK105 (penpulimab) is a differentiated PD-1 monoclonal antibody, which is being evaluated in combination with Anlotinib HCl for the first-line (1L) treatment of advanced hepatocellular carcinoma.
Product Name : AK105
Product Type : Antibody
Upfront Cash : Inapplicable
November 22, 2024
Lead Product(s) : Penpulimab,Anlotinib Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable